[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335677-105":59,"doc-detail-335677-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","study-protocol-for-adaptive-chemotherapy-for-ovarian-cancer-actov-a-multicentre-phase-ii-randomised-controlled-trial-to-evaluate-adaptive-therapy-efficacy","Study protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv) - a multicentre phase II randomised controlled trial to evaluate adaptive therapy efficacy","","Protocol for ACTOv describes a phase II, multicentre, randomised controlled trial assessing adaptive therapy with carboplatin in women with relapsed platinum-sensitive high-grade serous or high-grade endometrioid ovarian, fallopian tube, or peritoneal cancer. Eligibility requires progression at least 6 months after day 1 of the last platinum-based chemotherapy cycle. Eighty participants receive 1:1 standard therapy or adaptive therapy, dosing guided by CA125 changes, with modified progression-free survival as the primary endpoint.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/study-protocol-for-adaptive-chemotherapy-for-ovarian-cancer-actov-a-multicentre-phase-ii-randomised-controlled-trial-to-evaluate-adaptive-therapy-efficacy/335677/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/study-protocol-for-adaptive-chemotherapy-for-ovarian-cancer-actov-a-multicentre-phase-ii-randomised-controlled-trial-to-evaluate-adaptive-therapy-efficacy/335677.png","ImageObject",300,407,{"name":92,"@type":93},"Genevieve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the ACTOv trial evaluating?","Question",{"text":112,"@type":113},"ACTOv evaluates whether an adaptive therapy (AT) regimen with carboplatin is more effective than standard therapy in women with relapsed platinum-sensitive high-grade ovarian-related cancers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How is the adaptive carboplatin dose determined in ACTOv?",{"text":117,"@type":113},"The trial starts with carboplatin dose based on AUC × 5 and then modifies dosing according to changes in the serum biomarker CA125 as a proxy for total tumour burden.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the primary endpoint used to judge efficacy?",{"text":121,"@type":113},"The primary endpoint is modified progression-free survival, assessed using RECIST 1.1 compared with the baseline pre-randomisation scan rather than the radiological nadir.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335677,1790618033,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Open access Protocol  \nTo cite: Mukherjee UA, Hockings H, Counsell N, et al. Study protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv): a multicentre phase II randomised controlled trial to evaluate the efficacy of adaptive therapy (AT)  \nwith carboplatin, based on changes in CA125, in patients with relapsed platinumsensitive high-grade serous or high-grade endometrioid ovarian cancer. BMJ Open 2024;14:e091262 . doi:10 . 1136/ bmjopen-2024-091262  \n► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[bmjopen-2024-091262](bmjopen-2024-091262)) .  \nReceived 16 July 2024  \nAccepted 22 November 2024  \n© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nProfessor Michelle Lockley; [m.lockley@qmul.ac.uk](m.lockley@qmul.ac.uk)  \nStudy protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv): a multicentre phase II randomised controlled trial to evaluate the efficacy of adaptive therapy (AT) with carboplatin, based on changes in CA125, in patients with relapsed platinum-sensitive high-grade serous or high-grade endometrioid ovarian cancer  \nUma Anne Mukherjee  ,1 Helen Hockings  ,2 Nicholas Counsell  ,1 Apini Patel  ,3 Priya Narayanan,3 Katie Wilkinson  ,1 Harjot Dhanda  ,1 Kathy Robinson,1 Iain McNeish  ,4 Alexander R A Anderson  ,5 Rowan Miller  ,2,3 Charlie Gourley  ,6 Trevor Graham  ,7  \nMichelle Lockley  3,8  \nABSTRACT  \nIntroduction Adaptive ChemoTherapy for Ovarian cancer (ACTOv) is a phase II, multicentre, randomised controlled trial, evaluating an adaptive therapy (AT) regimen with carboplatin in women with relapsed, platinum-sensitive high-grade serous or high-grade endometrioid cancer of the ovary, fallopian tube and peritoneum whose disease has progressed at least 6 months after day 1 of the last cycle of platinum-based chemotherapy. AT is a novel, evolutionarily informed approach to cancer treatment, which aims to exploit intratumoral competition between drug-sensitive and drug-resistant tumour subpopulations by modulating drug dose according to a patient’s own response to the last round of treatment. ACTOv is the first clinical trial of AT in this disease setting.  \nMethods and analysis 80 patients will be randomised 1:1 to standard therapy (control) or AT (investigational) arms. The starting and maximum carboplatin dose in both arms is area under the curve (AUC) ×5 according to absolute nuclear medicine glomerular filtration rate. The AT regimen will modify the carboplatin dose according to changes in the serum biomarker CA125, a proxy measure of total tumour burden. Patients will receive treatment intravenously every 21 days for a maximum of 6 and 12 cycles in the control and investigational arms, respectively. The primary endpoint is modified progression-free survival (investigator-assessed using RECIST 1.1 (Response Evaluation Criteria in Solid Cancers) compared with the baseline prerandomisation scan rather than the radiological nadir), clinical progression or death from any  \ncause. Secondary endpoints will include acceptability, deliverability, compliance, toxicity, CA125, quality of life and overall survival. ACTOv is open to National Health Service hospitals throughout the UK, recruitment is anticipated to take 36 months across 10 sites and will be managed by the Cancer Research UK and University College London Cancer Trials Centre.  \nEthics and dissemination The trial has been reviewed and received approval from the London—Dulwich Research Ethics Committee (REC) . Results of the trial will be disseminated through publication in peer-reviewed journals.  \nTrial registration number NCT05080556.  \nINTRODUCTION  \nOvarian cancer treatment  \nOvarian cancer is th","cbCairs8gIdRBtFD","https://ap.wps.com/l/cbCairs8gIdRBtFD","pdf",1119012,"English","# Abstract\n# Introduction\n# Strengths and Limitations of the Study","[{\"question\":\"What is the ACTOv trial evaluating?\",\"answer\":\"ACTOv evaluates whether an adaptive therapy (AT) regimen with carboplatin is more effective than standard therapy in women with relapsed platinum-sensitive high-grade ovarian-related cancers.\"},{\"question\":\"How is the adaptive carboplatin dose determined in ACTOv?\",\"answer\":\"The trial starts with carboplatin dose based on AUC × 5 and then modifies dosing according to changes in the serum biomarker CA125 as a proxy for total tumour burden.\"},{\"question\":\"What is the primary endpoint used to judge efficacy?\",\"answer\":\"The primary endpoint is modified progression-free survival, assessed using RECIST 1.1 compared with the baseline pre-randomisation scan rather than the radiological nadir.\"}]","Study protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv) - a multicentre phase II randomised controlled trial to evaluate adaptive therapy efficacy | PDF",1790011909,23]